Early Access — free while we kick the tires
EdgarHawk

IRWD IRONWOOD PHARMACEUTICALS INC Insider Trading

Latest: Director Sold $20.5M of Shares · Mar 2026
2 filings analyzed · Latest 2026-03-17
Insider buys
0
Insider sells
2
Unique insiders
2
Direction
Net selling
March 2026
2026-03-17
high
DENNER ALEXANDER J Sell
6,730,800 shares
$20,530,448
@ $3.05
Significance 7/10

IRWD Director DENNER ALEXANDER J sold 6,730,800 shares (6.73M) for $20,530,448.00 on 2026-03-17, reducing holdings by -42.3%.

Director Denner divested 6,730,800 shares across 2 separate sales on 2026-03-17 at a blended average price of $3.05, raising $20,530,448.00 and reducing his post-transaction holdings to 9,188,635 shares from 15,919,435 shares. This represents a substantial reduction of -42.3% of his pre-transaction position. The timing of this large sale occurs against a backdrop of material equity deterioration: the stock trades at $3.25 (current), down -27.8% over 30 days and -39.7% from its 52-week high of $5.39. Across his cross-ticker track record, Denner's 3 prior sells averaged +1.4% 30-day returns and +16.8% 90-day returns, with a 0.00% well-timed rate on those prior sales—indicating his past sells occurred before subsequent stock recoveries. The company's fundamentals show annual revenue decline of -15.7% year-over-year despite positive current-quarter net income of $40,080,000.00, and the P/E of 10.16 reflects a compressed valuation. This sale warrants investor attention given its substantial scale relative to the director's historical holdings and the stock's recent downward momentum.

February 2026
2026-02-25
high
MCCOURT Thomas A Sell
Chief Executive Officer
198,283 shares
$739,929
@ $3.73
Significance 7/10

IRWD CEO Thomas McCourt sells 198,283 shares (11.8% of holdings) at $3.73 avg; stock now -35.1% in 30 days, -37.7% from 52-week high.

CEO Thomas McCourt executed 2 separate sales totaling 198,283 shares for $739,929.33 on Feb 23-24, 2026, reducing his holdings by 11.8% to 1,489,002 shares. His prior sale at IRWD (Feb 2024) was well-timed, with the stock declining 54.1% over the subsequent 90 days. This current filing occurs in the context of sharply negative price action: IRWD is -35.1% over the past 30 days and -37.7% from its 52-week high of $5.39, now trading at $3.36. Company fundamentals show annual revenue declined 20.6% year-over-year, though the latest quarter posted $122.1M in revenue and $40.1M net income. The timing of this CEO reduction against the 30-day and 52-week drawdowns, combined with his track record of well-timed exits, warrants investor attention to whether the stock's recent deterioration reflects forward visibility by management.

Insiders here also file at

Get alerts for IRWD

Add IRWD to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access